E. Budinska, V. Popovici, S. Tejpar, D. 'ario, G. Lapique et al., Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer, J Pathol, vol.231, pp.63-76, 2013.

D. Sousa, E. Melo, F. Wang, X. Jansen, M. Fessler et al., Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions, Nat Med, vol.19, pp.614-622, 2013.

L. Marisa, A. De-reynies, A. Duval, J. Selves, M. P. Gaub et al., Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS Med, vol.10, 2013.

P. Roepman, A. Schlicker, J. Tabernero, I. Majewski, S. Tian et al., Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int J Cancer, vol.134, pp.552-62, 2014.

A. Sadanandam, C. A. Lyssiotis, K. Homicsko, E. A. Collisson, W. J. Gibb et al., A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat Med, vol.19, pp.619-644, 2013.

A. Schlicker, G. Beran, C. M. Chresta, G. Mcwalter, A. Pritchard et al., Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines, BMC Med Genomics, vol.5, p.66, 2012.

J. Guinney, R. Dienstmann, X. Wang, A. De-reyniès, A. Schlicker et al., The consensus molecular subtypes of colorectal cancer, Nat Med, vol.21, pp.1350-1356, 2015.

S. Martin-lannerée, T. Z. Hirsch, J. Hernandez-rapp, S. Halliez, J. L. Vilotte et al., PrPC from stem cells to cancer, Front Cell Dev Biol, vol.2, p.55, 2014.

A. Aguzzi and A. M. Calella, Prions: protein aggregation and infectious diseases, Physiol Rev, vol.89, pp.1105-52, 2009.

T. Z. Hirsch, S. Martin-lannerée, M. , and S. , Functions of the prion protein, Prog Mol Biol Transl Sci, vol.150, pp.1-34, 2017.

E. Malaga-trillo, G. P. Solis, Y. Schrock, C. Geiss, L. Luncz et al., Regulation of embryonic cell adhesion by the prion protein, PLoS Biol, vol.7, p.55, 2009.

A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci U S A, vol.102, pp.15545-50, 2005.

, Comprehensive molecular characterization of human colon and rectal cancer, Nature, vol.487, pp.330-337, 2012.

E. Medico, M. Russo, G. Picco, C. Cancelliere, E. Valtorta et al., The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets, Nat Commun, vol.6, p.7002, 2015.

T. Aparicio, B. Linot, L. Malicot, K. Bouché, O. Boige et al., FOLFIRI +bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802). Dig Liver Dis Off, J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.47, pp.271-273, 2015.

T. Aparicio, F. Ghiringhelli, V. Boige, L. Malicot, K. Taieb et al., Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, pp.674-81, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01728824

I. Macgregor, J. Hope, G. Barnard, L. Kirby, O. Drummond et al., Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components, Vox Sang, vol.77, pp.88-96, 1999.

A. Calon, E. Lonardo, A. Berenguer-llergo, E. Espinet, X. Hernando-momblona et al., Stromal gene expression defines poor-prognosis subtypes in colorectal cancer, Nat Genet, vol.47, pp.320-329, 2015.

A. Sveen, J. Bruun, P. W. Eide, I. A. Eilertsen, L. Ramirez et al., Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies, Clin Cancer Res Off J Am Assoc Cancer Res, vol.24, pp.794-806, 2018.

T. I. Roumeliotis, S. P. Williams, E. Gonçalves, C. Alsinet, D. C. Velasco-herrera et al., Genomic determinants of protein abundance variation in colorectal cancer cells, Cell Rep, vol.20, pp.2201-2215, 2017.

K. Bracht, A. M. Nicholls, Y. Liu, and W. F. Bodmer, 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency, Br J Cancer, vol.103, pp.340-346, 2010.

X. Varelas, The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease, Dev Camb Engl, vol.141, pp.1614-1640, 2014.

I. Lian, J. Kim, H. Okazawa, J. Zhao, B. Zhao et al., The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation, Genes Dev, vol.24, pp.1106-1124, 2010.

F. Zanconato, M. Forcato, G. Battilana, L. Azzolin, E. Quaranta et al., Genomewide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth, Nat Cell Biol, vol.17, pp.1218-1245, 2015.

A. Gregorieff, Y. Liu, M. R. Inanlou, Y. Khomchuk, and J. L. Wrana, Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer, Nature, vol.526, pp.715-723, 2015.

E. Desot, L. De-mestier, J. Volet, C. Delmas, B. Garcia et al., Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Köhne's risk classification. Dig Liver Dis Off, J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.45, pp.330-335, 2013.

M. Mehrpour and P. Codogno, Prion protein: from physiology to cancer biology, Cancer Lett, vol.290, pp.1-23, 2010.

Y. Cheng, L. Tao, J. Xu, Q. Li, J. Yu et al., CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients, Mol Carcinog, vol.53, pp.686-97, 2013.

M. H. Lopes, T. G. Santos, B. R. Rodrigues, N. Queiroz-hazarbassanov, I. W. Cunha et al., Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival, Oncogene, vol.34, pp.3305-3319, 2014.

L. Provenzano, Y. Ryan, D. A. Hilton, J. Lyons-rimmer, D. F. Maze et al., Cellular prion protein (PrPC) in the development of Merlin-deficient tumours, Oncogene, vol.36, pp.6132-6174, 2017.

L. Du, G. Rao, H. Wang, B. Li, W. Tian et al., CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer, Cancer Res, vol.73, pp.2682-94, 2013.

R. P. Iglesia, M. B. Prado, L. Cruz, V. R. Martins, T. G. Santos et al., Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells, Stem Cell Res Ther, vol.8, p.76, 2017.

T. De-lacerda, C. , B. Giudice, F. S. Dias, M. De-oliveira et al., Prion protein binding to HOP modulates the migration and invasion of colorectal cancer cells, Clin Exp Metastasis, vol.33, pp.441-51, 2016.

C. Chieng and Y. Say, Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicininduced apoptosis, Tumour Biol J Int Soc Oncodeve Biol Med, vol.36, pp.8107-8127, 2015.

J. H. Lee, C. W. Yun, and S. H. Lee, Cellular prion protein enhances drug resistance of colorectal cancer cells via regulation of a survival signal pathway, Biomol Ther, vol.26, pp.313-334, 2018.

A. P. Wiegmans, J. M. Saunus, S. Ham, R. Lobb, J. R. Kutasovic et al., Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer, JCI Insight, vol.5, 2019.

R. Dienstmann, L. Vermeulen, J. Guinney, S. Kopetz, S. Tejpar et al., Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer, Nat Rev Cancer, vol.17, p.268, 2017.

A. W. Hong, Z. Meng, and K. Guan, The Hippo pathway in intestinal regeneration and disease, Nat Rev Gastroenterol Hepatol, vol.13, pp.324-361, 2016.

F. Zanconato, M. Cordenonsi, and S. Piccolo, YAP/TAZ at the roots of cancer, Cancer Cell, vol.29, pp.783-803, 2016.